| dc.contributor.author |
Navarese, Eliano Pio |
| dc.contributor.author |
Buffon, Antonino |
| dc.contributor.author |
Koziński, Marek |
| dc.contributor.author |
Obońska, Karolina |
| dc.contributor.author |
Rychter, Marcin |
| dc.contributor.author |
Kunadian, Vijay |
| dc.contributor.author |
Austin, David |
| dc.contributor.author |
De Servi, Stefano |
| dc.contributor.author |
Sukiennik, Adam |
| dc.contributor.author |
Kubica, Jacek |
| dc.date.accessioned |
2013-04-17T12:10:55Z |
| dc.date.available |
2013-04-17T12:10:55Z |
| dc.date.issued |
2013-04-17 |
| dc.identifier.citation |
QJM: An International Journal of Medicine, vol. 106, 2, 2013, pp. 105 -115 |
| dc.identifier.issn |
1460-2393 |
| dc.identifier.uri |
http://repozytorium.umk.pl/handle/item/489 |
| dc.description.abstract |
Until a few years ago, the mainstay of anti-platelet
therapy in patients with acute coronary syndrome
(ACS) was the combination of aspirin and clopidogrel,
a P2Y12 receptor inhibitor. However, current
clinical practice has now changed with the introduction
of ticagrelor, a more potent cardiovascular
drug than clopidogrel, without the limitations
related to clopidogrel therapy. In this review, we
provide a critical overview of ticagrelor in ACS,
highlight the results with ticagrelor in several subgroups
of patients and discuss the future trials. |
| dc.language.iso |
eng |
| dc.rights |
info:eu-repo/semantics/openAccess |
| dc.subject |
acute coronary syndrome |
| dc.subject |
ticagrelor |
| dc.subject |
critical overview |
| dc.title |
A critical overview on ticagrelor in acute coronary syndromes |
| dc.type |
info:eu-repo/semantics/article |
